Just Accepted
This article has been peer reviewed and accepted for publication. It is in production and has not been edited, so may differ from the final published form.
The Medicines Repurposing Program – a critical perspective.
Abstract
The Medicine Repurposing Program was launched on 1 March 2024. It provides a pathway for registering and subsidizing off-label medicines of significant public health benefit but which sponsors have no financial incentive to pursue. This article provides a short overview and critical analysis of the program. One concern that emerges is that commercial sponsors still retain de facto veto power over which off-label uses are prioritized and so have the capacity to sway the process. Simple suggestions are proposed to help mitigate this risk.
AH24077 Accepted 18 April 2024
© CSIRO 2024
